A Florida woman was arrested for operating an unlicensed “medspa” in her backyard shed, causing facial paralysis in a patient. But calling this a medspa story misses the real issue: legitimate-looking practices that cut corners on sourcing while hiding in plain sight. The industry needs real oversight to protect compliant medspas from being lumped in with backyard operations.

John Oliver addresses the lack of oversight in the medspa indusry on Last Week tonight.

10 case of botulism from Botox suspected from Canton, MA neighbor Milton. Read about the closer of Rodrigo Beauty plus more about the problem in this fast growing industry.

Medspas offering compounded semaglutide products must act fast after a major FDA ruling. Find out what this means for your business.

Ohio Attorney General Dave Yost has warned 14 med spas for making misleading claims about compounded semaglutide drugs. Discover what your med spa needs to update to stay compliant.

Trump’s tariffs could drive up Botox prices in 2025. Here’s what medspa owners need to know and how to prepare.

Eli Lilly is suing Empower Pharmacy over unapproved tirzepatide products. If your medspa offers compounded weight loss medications, here’s what you must do now to stay compliant.

XWELL is making a bold move into the medical spa industry with plans to acquire multiple medspas by 2025. This shift aligns with the growing trend of mergers, acquisitions, and corporate-backed medspa brands. What does this mean for independent medspa owners?

A Texas federal judge’s ruling on March 5, 2025, ends compounded versions of Eli Lilly’s Zepbound and Mounjaro, affecting medspas relying on affordable weight loss drugs. Discover the implications for costs and care.

Novo Nordisk’s new $499 direct-to-consumer Wegovy program threatens to eliminate a major revenue stream for medspas nationwide. Coming right after the FDA ended the semaglutide shortage, this strategic move could force significant layoffs and closures across the aesthetic wellness industry that has relied on compounded semaglutide services.

The FBI warns that some compounding pharmacies, medspas, and weight loss clinics are selling misrepresented semaglutide, posing serious health risks. Find out how to protect your business and patients.

Compounding pharmacies are taking legal action against the FDA to protect patient access to semaglutide. Learn why this matters for medspa owners, patients, and the future of healthcare.

Kyle Scheele isn’t your typical medspa conference speaker—and that’s exactly why his keynote matters. Find out how his entrepreneurial approach challenges the clinical thinking that holds most medspa owners back, and why his “just try it” philosophy might be the wake-up call the aesthetics industry desperately needs.

Lindsay Malachowski bids farewell to SKINNEY Medspa after eight years, acknowledging co-founders Adriana and Marisa Martino and the team’s collective success.

Allergan Aesthetics is launching three state-of-the-art training centers in the U.S. to expand access to high-quality aesthetics education for medical professionals.

Eli Lilly’s lawsuits against medspas selling compounded tirzepatide highlight the risks of offering unapproved weight-loss treatments. Learn why compliance is crucial for protecting your business.

With the FDA’s tirzepatide shortage resolved, compounding pharmacies are introducing formulations with Vitamin B. Here’s what medspa owners and providers must know about compliance and patient care.